MAP2K7 and non-small cell lung carcinoma: We also reported that siRNA-mediated mutant KRAS knockdown and pharmacological inhibitors of MEK and ERK reduced PD-L1 expression in NSCLC cells with KRAS mutations and PD-L1 overexpression [97].